Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117374 | 0.90 | MARS1 (1.00) | MARS1RPA1 | |
| SCHEMBL27714738 | 0.81 | MARS1 (0.67) | MARS1RPA1 | |
| SCHEMBL116301 | 0.75 | MARS1 (1.00) | MARS1RPA1 | |
| SCHEMBL8742241 | 0.74 | RPA1 (0.78) | MARS1RPA1 | |
| SCHEMBL29890709 | 0.72 | MARS1 (0.55) | MARS1 | |
| SCHEMBL117471 | 0.71 | MARS1 (1.00) | MARS1RPA1 | |
| SCHEMBL31139190 | 0.71 | MARS1 (0.54) | MARS1 | |
| SCHEMBL117499 | 0.71 | MARS1 (1.00) | MARS1 | |
| SCHEMBL17156375 | 0.71 | MARS1 (0.55) | MARS1 | |
| SCHEMBL118666 | 0.70 | MARS1 (1.00) | MARS1RPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885RPA1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.